Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

MCL Paradigm Moves Toward More Nuanced Risk Stratification, Novel Treatments

June 2nd 2020

Jia Ruan, MD, PhD, discusses the current risk-stratification parameters and the evolution of treatment from high-intensity chemoimmunotherapy to novel therapy in mantle cell lymphoma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

June 2nd 2020

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

May 30th 2020

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Dr. Jain on Next Steps for Venetoclax in Relapsed MCL

May 22nd 2020

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

Dr. Miklos on Development Process for KTE-X19 in MCL

May 20th 2020

David Miklos, MD, discusses the process of developing KTE-X19 and the ZUMA-2 trial in mantle cell lymphoma.

Dr. Jain on Response and Resistance to Venetoclax in Relapsed/Refractory MCL

May 20th 2020

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Venetoclax Shows Marked Responses and Distinct Resistance Mechanisms in MCL

May 19th 2020

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Venetoclax Shows Marked Responses and Distinct Resistance Mechanisms in MCL

May 19th 2020

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Precision Medicine: The Next Paradigm Shift in MCL

May 17th 2020

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

Dr. Wang on Research Trends in MCL

May 16th 2020

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Dr. Zelenetz on Progress Made in MCL Treatment

May 15th 2020

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Dr. Zelenetz on Progress Made in MCL Treatment

May 14th 2020

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Dr. Wang on the Evolution of Treatment in MCL

May 14th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Smith on Frontline Treatment Options in MCL

May 14th 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Dr. Fenske on the Utility of Next-Generation BTK Inhibitors in MCL

May 13th 2020

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCL

May 13th 2020

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Dr. Wang on the Evolution of Treatment in MCL

May 13th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 13th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Gerson on Clinical Trial Accrual in MCL

May 13th 2020

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.